Skip to main content

Global Hemophilia Therapeutics Market : Market Sizing with Competitive Landscape by 2021

Press Release   •   Feb 04, 2017 02:08 EST

 According to the U.S. Centers for Disease Control and Prevention, hemophilia occurs in approximately one in 5,000 live births. Painful prolonged headache, sudden pain, swelling and warmth in large joints, bleeding from an injury, double vision, neck pain, extreme fatigue, and repeated vomiting are some of the signs and symptoms of hemophilia. Damage to joints, infection, adverse reaction to clotting factor treatment, and deep internal bleeding are among the complications related to hemophilia.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/4727

The disorder is diagnosed through a blood test showing blood clot deficiency. There is no cure for hemophilia, although therapies to stop bleeding depend upon the type of hemophilia. In mild hemophilia A, slow injection of the hormone desmopressin (DDAVP) - the synthetic version of vasopressin - stimulates the release of more clotting factor to stop bleeding. Moreover, in moderate to severe hemophilia or hemophilia B recombinant blood clotting factor or clotting factor derived from donated human blood is infused to cease bleeding. Patients with severe hemophilia are treated with the help of a routine treatment regimen, called prophylaxis, so as to maintain clotting factor levels in their bloodstream.

North America dominates the global market for hemophilia therapeutics due to the high rate of awareness about hemophilia treatment in the region. Asia Pacific is expected to show high growth rates over the next five years in the global hemophilia therapeutics market, with China and India being the fastest-growing markets in the Asia-Pacific region. The key driving forces for the hemophilia therapeutics market in developing countries are: A large pool of patients, increasing medical tourism, heightened awareness regarding overall healthcare, improving healthcare infrastructure, and augmented healthcare expenditure in the region.

Key factors driving the growth of the global hemophilia therapeutics market are: Development of novel coagulating factors, improving healthcare infrastructure in developing countries, increasing healthcare spending, expanding medical tourism in developing countries, and technological advancements in hemophilia drug innovation. However, the lack of awareness about hemophilia, and high cost of treatment, act as major restraints for the growth of the global hemophilia therapeutics market.

To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/4727

Gene therapy and increasing approval of drugs for the treatment of hemophilia are poised to create opportunities for the global hemophilia therapeutics market.

Key segments covered in this report are:

  • By type
    • Hemophilia A
    • Hemophilia B
  • By drugs
    • Desmopressin
    • Octocogalfa
    • Nonacogalfa
    • Others

Top companies profiled in this report are:

  • Bayer AG
  • Pfizer, Inc.
  • Novo Nordisk A/S
  • Baxter International Inc.
  • Biogen Idec, Inc.
  • Genetics Institute
  • Alpha Therapeutics Corporation
  • Expression Therapeutics
  • Swedish Orphan Biovitrum AB.

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research

305 Broadway

7th Floor, New York City, 

NY 10007, United States,

USA - Canada Toll Free: 800-961-0353

Email: sales@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

Comments (0)

Add comment

Comment